Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

BiOasis Technologies Inc V.BTI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s): BIOAF

biOasis Technologies, Inc. is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
Price: $0.99 | Change: $-0.08 | % Change: -7.48%
Volume: 55,425 | Day High/Low: 1.01/0.99 | 52 Week High/Low: 1.45/0.67

View modes: 
4 stars

RE:just catching up

G1945V, we don't expect biOasis to do any clinical trials in-house. We may have up until a few months ago, but only with BT2111, the only in-house drug that has been developed to any degree by biOasis...read more
2.5 stars

just catching up

So, if I understand your very impressive postings on this bullborad, Bioasis is still experimenting on mice. with its BBB delivery system thus far. So human trials are far in the distant future ....Is...read more
5 stars

email to bioasis

So i finally got around to emailing and asking a few simple questions, not that its going to change anything as most of the people on here have probably already tried contacting bioasis... I've asked...read more
0 stars


no need to apologize, i get the whole frustration thing. but if there is anything of significance to come, i don't think the market will pay any attention to the $1.00 mark. this thinking might be...read more
0 stars


Apologies...it's the 1000 share trades pushing it down a few pennies per day or the 100 share trade that drop it 6% on an open.  Just frustration as we could be weeks away from anything still and by...read more
0 stars


robran, volume is farrrr too low to call anything a trend....any sort of TA is useless. it could just as easy close at 1.20 or .80 tomorrow and mean nothing, unless there's volume. dug  rate and reply
0 stars


Really?  Shows $0.99 everywhere I look this afternoon. Trouble is the trend, regardless........  rate and reply
3 stars


For the record, the closing trade was on the Chi-X ATS and the price was $1.01, not $0.98. Not much of a difference but the optics are better. jdstox  rate and reply
1 star

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche - Kadcyla

....and there we go!  rate and reply
3 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche - Kadcyla

This will be brought below $1 by day's end...my concern is ithat the SP will continue to decline leading into news and that any news may only bring us back up to where we have been sitting the last...read more
2.5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche - Kadcyla

Ok no problem...see ubguys here in three months still at a dollar....and a year from then same price......smoke and mirrors is all we seem to get....shows in the share price ...and shows how good...read more
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:Roche - Kadcyla

Stop, oilpatch. Think!! MedImmune is using Transcend 2, as they did in the first part of their collaboration with biOasis. Transcend 2 is the only future for Transcend. Don't you read anything? The...read more
1 star

RE:RE:RE:RE:RE:RE:RE:Roche - Kadcyla

Lets just figure out whats goingbon with trancend 1 before we start makin names up for what they are doing with meddimune.....for zchrists sakes were trading at a dollar after a liscenxing deal...read more
4 stars

RE:RE:RE:RE:RE:RE:Roche - Kadcyla

I would think, as I stated, that the filing of IP protection is related to there being a new Transcend 2/trastuzumab conjugate, and that BT2111 is dead, unless biOasis renames the new entity with name...read more
0 stars

RE:RE:RE:RE:RE:Roche - Kadcyla

From what I've heard, I believe that something interesting resulted in the BT2111 studies and that the delay is due to the need to file IP. This view is corroborated by the recent email: there are...read more
4 stars

RE:RE:RE:RE:Roche - Kadcyla

Sir_Holler, does BT2111 still exist? Does biOasis or a new owner of BT2111's replacement need to do new tests on a New Chemical Entity - the BT2111 replacement? And would a bidder for the BT2111...read more
3.5 stars

RE:RE:RE:Roche - Kadcyla

"Additional studies are underway at TTUHSC to assess the effect of BT2111 on improving the survival of mice in a brain metastasis model of HER2+ breast cancer." MD&A  rate and reply
3.5 stars

RE:RE:Roche - Kadcyla

Sir_Holler, I have no knowledge of any longevity tests being done with BT2111 and mice. As a matter of fact, I would question whether BT2111 will even survive at all. It is, after all, a conjugate...read more
1 star

I see this is on sale

I wonder when the clearance sale and then the garage sale will start? Anyone have any insights... Positive side I can stil buy a few more shares of ico with every bti << how JDsux determines if his...read more
5 stars

RE:Roche - Kadcyla

even more reason to add to the potential blockbuster value of bt2111!! the presentation at AACR, the news from 2013 and the increasing need and desire for pharma to participate in the biosimilar and...read more